SUNHERE(300452)2024-04-25 09:05Financial Performance - The company's revenue for Q1 2024 was ¥237,688,540.94, a decrease of 4.05% compared to ¥247,713,230.60 in the same period last year[4] - Net profit attributable to shareholders was ¥49,815,076.00, reflecting a slight increase of 0.86% from ¥49,388,285.35 year-on-year[4] - Net profit for Q1 2024 was CNY 50,518,085.80, slightly down from CNY 50,996,500.65 in the previous period, representing a decrease of 0.94%[21] - The net profit attributable to the parent company for Q1 2024 is CNY 49,815,076, an increase from CNY 49,388,285 in the previous period, reflecting a growth of approximately 0.87%[22] - The total comprehensive income for the parent company in Q1 2024 is CNY 49,815,155, compared to CNY 49,388,285 in the previous period, indicating a similar growth trend[22] Cash Flow - The net cash flow from operating activities was -¥10,229,557.31, a significant decline of 712.67% compared to -¥1,258,762.15 in the previous year[4] - The net cash flow from operating activities for Q1 2024 is -CNY 10,229,557, worsening from -CNY 1,258,762 in the previous period[25] - Cash inflow from operating activities totaled CNY 179,860,893, while cash outflow was CNY 190,090,451, leading to a negative cash flow[25] - The cash flow from investing activities for Q1 2024 is -CNY 4,082,863, an improvement from -CNY 9,997,024 in the previous period[26] - Cash flow from financing activities resulted in a net outflow of -CNY 23,377,116, compared to a slight inflow of CNY 95,294 in the previous period[26] - The ending cash and cash equivalents balance for Q1 2024 is CNY 112,793,039, slightly up from CNY 110,987,658 in the previous period[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,543,295,888.33, showing a marginal increase of 0.04% from ¥1,542,710,563.50 at the end of the previous year[4] - Total liabilities decreased to CNY 579,867,042.92 from CNY 607,461,116.85, a decline of 4.55%[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,668[13] - The largest shareholder, Yin Zhenglong, holds 26.90% of the shares, totaling 63,057,454 shares[13] - Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. holds 11.20% of the shares, totaling 26,254,059 shares[13] - The company repurchased 1,825,500 shares by the end of Q1 2024[14] - The total number of restricted shares held by Yin Zhenglong is 47,293,090, which are subject to lock-up due to executive restrictions[16] - The company has a total of 47,660,415 restricted shares, with 22,620 shares released during the period[16] - There are no significant changes in the top ten shareholders or their shareholding status compared to the previous period[14] Operational Metrics - The company's basic earnings per share remained stable at ¥0.21, unchanged from the same period last year[4] - The company received CNY 178,638,206.45 from sales of goods and services in Q1 2024, compared to CNY 168,179,810.14 in the previous period[24] - Accounts receivable increased by 69.49% to ¥138,800,100.00, primarily due to increased sales[7] - Accounts receivable increased to CNY 138,800,059.55 from CNY 81,892,875.33, reflecting a growth of 69.2%[19] - Cash and cash equivalents decreased to CNY 137,439,678.63 from CNY 173,962,875.93, a decline of 20.98%[19] - Inventory decreased to CNY 73,159,391.03 from CNY 94,103,555.20, a reduction of 22.19%[19] Investment and Expenses - The company's investment income for the period was ¥3,745,773.20, an increase of 169.23% year-on-year, attributed to higher returns from financial products[10] - The company reported an increase in financial income, with investment income rising to CNY 3,745,773.20 from CNY 1,391,267.41, an increase of 169.9%[21] - The company reported a significant increase in financial expenses, which rose by 410.38% to ¥2,751,700.00, mainly due to interest expenses from convertible bonds[9] - The company plans to continue focusing on research and development, with R&D expenses at CNY 11,783,747.62, slightly down from CNY 12,592,178.62 in the previous period[21] Other Information - The company has not disclosed any new product or technology developments in the current report[15] - The company has not reported any mergers or acquisitions in the current quarter[15] - The financial statements for Q1 2024 are prepared and available for review[17] - Total operating revenue for Q1 2024 was CNY 237,688,540.94, a decrease of 4.12% from CNY 247,713,230.60 in the previous period[21] - Total operating costs for Q1 2024 were CNY 189,620,354.92, down 2.43% from CNY 194,560,102.43 in the previous period[21]